Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Operations (Unaudited)

v3.22.2.2
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Operating expenses:        
Research and development $ 3,872 $ 2,105 $ 9,105 $ 6,061
General and administrative 1,822 1,848 4,530 4,458
Legal settlement 1,600
Impairments 19,092
Total operating expenses 5,694 3,953 34,327 10,519
Loss from operations (5,694) (3,953) (34,327) (10,519)
Other (expense) income:        
Interest expense, net (1) (1) (2) (4)
Foreign exchange loss (5) (4) (19) (4)
Change in fair value of derivative liabilities 17 12 27
Total other (expense) income, net (6) 12 (9) 19
Net loss $ (5,700) $ (3,941) $ (34,336) $ (10,500)
Net loss per common share, basic and diluted $ (0.70) $ (0.48) $ (4.23) $ (1.44)
Weighted average number of common shares outstanding, basic and diluted 8,143 8,143 8,143 7,108